Jefferies Group LLC Reiterates “Buy” Rating for Heron Therapeutics, Inc. (HRTX)
Heron Therapeutics, Inc. (NASDAQ:HRTX)‘s stock had its “buy” rating restated by equities research analysts at Jefferies Group LLC in a note issued to investors on Wednesday. Jefferies Group also issued estimates for Heron Therapeutics’ Q3 2017 earnings at ($0.89) EPS, Q4 2017 earnings at ($0.96) EPS, FY2017 earnings at ($3.52) EPS, FY2018 earnings at ($2.28) EPS and FY2019 earnings at ($1.00) EPS.
Several other research firms also recently weighed in on HRTX. Cowen and Company set a $40.00 price objective on shares of Heron Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 3rd. Aegis reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Heron Therapeutics in a report on Tuesday, July 18th. Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Thursday, August 10th. Zacks Investment Research downgraded shares of Heron Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 9th. Finally, ValuEngine raised shares of Heron Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. One equities research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company. Heron Therapeutics presently has an average rating of “Buy” and a consensus target price of $31.00.
Heron Therapeutics (NASDAQ HRTX) opened at 15.40 on Wednesday. Heron Therapeutics has a one year low of $12.21 and a one year high of $21.55. The stock has a 50 day moving average of $15.42 and a 200-day moving average of $14.64.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.10. The company had revenue of $8.51 million during the quarter, compared to analyst estimates of $4.53 million. Equities analysts expect that Heron Therapeutics will post ($3.73) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/jefferies-group-llc-reiterates-buy-rating-for-heron-therapeutics-inc-hrtx/1494256.html.
A number of large investors have recently modified their holdings of HRTX. Legal & General Group Plc increased its stake in shares of Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after buying an additional 1,098 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Heron Therapeutics during the first quarter worth $161,000. Quantbot Technologies LP increased its stake in shares of Heron Therapeutics by 2,619.6% in the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock worth $172,000 after buying an additional 12,024 shares during the last quarter. Highbridge Capital Management LLC increased its stake in shares of Heron Therapeutics by 1.6% in the fourth quarter. Highbridge Capital Management LLC now owns 15,697 shares of the biotechnology company’s stock worth $206,000 after buying an additional 252 shares during the last quarter. Finally, Old West Investment Management LLC acquired a new stake in shares of Heron Therapeutics during the first quarter worth $206,000.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.